NCT06417853View on ClinicalTrials.gov

Influenza a (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

267

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
H7N9 Influenza
Interventions
BIOLOGICAL

Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Injection

7.5 mcg Influenza A (H7N9) Injection

COMBINATION_PRODUCT

Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA)

12 mcg Influenza A (H7N9) Microarray Patch Delivery System (VXS-1219)

COMBINATION_PRODUCT

Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA)

25 mcg Influenza A (H7N9) Microarray Patch Delivery System (VXS-1219)

BIOLOGICAL

Adjuvanted Influenza A (H7N9) Monovalent Vaccine Injection

7.5 mcg Influenza A (H7N9) with MF59® Injection

COMBINATION_PRODUCT

Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, low dose adjuvant)

12 mcg Influenza A (H7N9) with 4 mcg QS21 Microarray Patch Delivery System (VXS-1219A)

COMBINATION_PRODUCT

Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, high dose adjuvant)

12 mcg Influenza A (H7N9) with 8 mcg QS21 Microarray Patch Delivery System (VXS-1219A)

COMBINATION_PRODUCT

Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, low dose adjuvant)

20 mcg Influenza A (H7N9) with 3.3 mcg QS21 Microarray Patch Delivery System (VXS-1219A)

COMBINATION_PRODUCT

Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, high dose adjuvant)

20 mcg Influenza A (H7N9) with 6.7 mcg QS21 Microarray Patch Delivery System (VXS-1219A)

DEVICE

Microarray Patch Delivery System

Vaccine free Microarray Patch Delivery System (VXS-1219U)

Trial Locations (4)

3002

Doherty Clinical Trials Ltd, East Melbourne

4101

University of Sunshine Coast Clinical Trials, South Brisbane

4506

University of Sunshine Coast Clinical Trials, Morayfield

4556

University of Sunshine Coast Clinical Trials, Sippy Downs

All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Vaxxas Pty Ltd

INDUSTRY

NCT06417853 - Influenza a (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) | Biotech Hunter | Biotech Hunter